SMARTAG
LIVE

Serial Number

85963028

Owner

CATALENT PHARMA SOLUTIONS, INC.

Attorney

Vanessa A. Ignacio

First Use Date

Oct 20, 2014

Filing Date

Jun 18, 2013

Add to watchlist:

No watchlists yet
View on USPTO

SMARTAG Trademark

Serial Number: 85963028 • Registration: 5054933

SMARTAG is a trademark filed by CATALENT PHARMA SOLUTIONS, INC. on June 18, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CATALENT PHARMA SOLUTIONS, INC. (64 trademarks)

14 Schoolhouse Road
Somerset, NJ 08873

Entity Type: 03

Trademark Details

Filing Date

June 18, 2013

Registration Date

October 4, 2016

First Use Anywhere

October 20, 2014

First Use in Commerce

October 20, 2014

Published for Opposition

December 2, 2014

Goods & Services

Pharmaceutical preparations for the prevention or treatment of human diseases, namely, diseases of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; chemical, biological and biochemical preparations for medical and pharmaceutical purposes, namely, antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity or such preparations used as linker or payload molecules therein used to treat cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; diagnostic preparations for medical purposes in connection with the diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; antibody preparations, namely, antibody or protein bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system, including antibody/protein-drug conjugates, antibody/protein-radiolabled conjugates and antibody/protein-imaging agent conjugates; chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system; biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system

Chemical, biochemical and biological reagents in the nature of or used to create or improve antibody-drug conjugates or any protein conjugated to a drug, poly nucleotide, another protein, chemical, or other functional entity used in industry and science; chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production for scientific use; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications for scientific use; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids for scientific use; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, flourocromes and radiolabels for medical research applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in basic scientific research and development, medical research; diagnostic preparations for scientific or research use in connection with antibody drug conjugates; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of cancer and diseases and disorders of the immune system, respiratory system, cardiovascular system, digestive system, endocrine system, lymphatic system, muscular system, skeletal system, nervous system, urinary system, integumentary system and reproductive system

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Oct 4, 2025 REM2
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 25, 2024 ASCK
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Oct 5, 2023 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Oct 5, 2023 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 5, 2023 APRE
TEAS SECTION 8 & 15 RECEIVED
Apr 4, 2023 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 4, 2021 REM1
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
May 22, 2019 ASCK
REGISTERED-PRINCIPAL REGISTER
Oct 4, 2016 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 31, 2016 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 30, 2016 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 9, 2016 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 6, 2016 AITU
USE AMENDMENT FILED
Jul 13, 2016 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 13, 2016 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 19, 2016 EXRA
SOU EXTENSION 1 GRANTED
Jan 15, 2016 EX1G
SOU EXTENSION 1 FILED
Jan 15, 2016 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 15, 2016 EEXT
PETITION TO DIRECTOR GRANTED
Sep 2, 2015 PCGR
ASSIGNED TO PETITION STAFF
Aug 31, 2015 APET
TEAS PETITION TO DIRECTOR RECEIVED
Aug 4, 2015 TPDR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 28, 2015 NOAM
POST PUBLICATION AMENDMENT – NOT ENTERED
Jul 25, 2015 CHPN
ASSIGNED TO PETITION STAFF
Jul 22, 2015 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jul 16, 2015 EPPA
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 16, 2015 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Dec 23, 2014 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2014 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 12, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 28, 2014 PREV
ASSIGNED TO LIE
Oct 28, 2014 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 9, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 17, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 17, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 17, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 2, 2014 GNRN
NON-FINAL ACTION E-MAILED
Apr 2, 2014 GNRT
NON-FINAL ACTION WRITTEN
Apr 2, 2014 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 11, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 10, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 10, 2014 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 16, 2013 GNRN
NON-FINAL ACTION E-MAILED
Sep 16, 2013 GNRT
NON-FINAL ACTION WRITTEN
Sep 16, 2013 CNRT
ASSIGNED TO EXAMINER
Sep 10, 2013 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Jun 28, 2013 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 27, 2013 NWOS
NEW APPLICATION ENTERED
Jun 21, 2013 NWAP